WO2017060750A1 - Use of a withania extract for the treatment of demyelinating deseases - Google Patents

Use of a withania extract for the treatment of demyelinating deseases Download PDF

Info

Publication number
WO2017060750A1
WO2017060750A1 PCT/IB2015/001979 IB2015001979W WO2017060750A1 WO 2017060750 A1 WO2017060750 A1 WO 2017060750A1 IB 2015001979 W IB2015001979 W IB 2015001979W WO 2017060750 A1 WO2017060750 A1 WO 2017060750A1
Authority
WO
WIPO (PCT)
Prior art keywords
ms
decrease
composition
extract
composition according
Prior art date
Application number
PCT/IB2015/001979
Other languages
English (en)
French (fr)
Inventor
Chérif RABHI
Léon Cariel
Jamal Ouazzani
Guillaume ARCILE
Original Assignee
Ethnodyne
Centre National De La Recherche Scientifique (Cnrs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethnodyne, Centre National De La Recherche Scientifique (Cnrs) filed Critical Ethnodyne
Priority to PCT/IB2015/001979 priority Critical patent/WO2017060750A1/en
Publication of WO2017060750A1 publication Critical patent/WO2017060750A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/67Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
PCT/IB2015/001979 2015-10-05 2015-10-05 Use of a withania extract for the treatment of demyelinating deseases WO2017060750A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/001979 WO2017060750A1 (en) 2015-10-05 2015-10-05 Use of a withania extract for the treatment of demyelinating deseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2015/001979 WO2017060750A1 (en) 2015-10-05 2015-10-05 Use of a withania extract for the treatment of demyelinating deseases
EP15798547.4A EP3359177A1 (en) 2015-10-05 2015-10-05 Use of a withania extract for the treatment of demyelinating deseases

Publications (1)

Publication Number Publication Date
WO2017060750A1 true WO2017060750A1 (en) 2017-04-13

Family

ID=54697611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/001979 WO2017060750A1 (en) 2015-10-05 2015-10-05 Use of a withania extract for the treatment of demyelinating deseases

Country Status (2)

Country Link
EP (1) EP3359177A1 (it)
WO (1) WO2017060750A1 (it)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110230551A1 (en) * 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
WO2014202469A1 (fr) 2013-06-17 2014-12-24 Ethnodyne Procede d'obtention d'un extrait de plante et compositions associees

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110230551A1 (en) * 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
WO2014202469A1 (fr) 2013-06-17 2014-12-24 Ethnodyne Procede d'obtention d'un extrait de plante et compositions associees

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRADL. M.; H. LASSMANN., ACTA NEUROPATHOL, vol. 19, 2010, pages 37 - 53
CHARLES ET AL., PNAS, vol. 97, 2000, pages 7585 - 7590
CHÉRIF RABHI ET AL: "Antiangiogenic-Like Properties of Fermented Extracts of Ayurvedic Medicinal Plants", JOURNAL OF MEDICINAL FOOD, vol. 18, no. 9, 1 September 2015 (2015-09-01), US, pages 1065 - 1072, XP055250185, ISSN: 1096-620X, DOI: 10.1089/jmf.2014.0128 *
CHIHIRO TOHDA: "ChemInform Abstract: Overcoming Several Neurodegenerative Diseases by Traditional Medicines - The Development of Therapeutic Medicines and Unraveling Pathophysiological Mechanisms", CHEMINFORM, vol. 39, no. 52, 23 December 2008 (2008-12-23), DE, pages 1159 - 1167, XP055250168, ISSN: 0931-7597, DOI: 10.1002/chin.200852253 *
GEETA MAKER-CLARK ET AL: "Integrative therapies for multiple sclerosis", DISEASE-A-MONTH., vol. 59, no. 8, 1 August 2013 (2013-08-01), US, pages 290 - 301, XP055250173, ISSN: 0011-5029, DOI: 10.1016/j.disamonth.2013.03.017 *
NAKAYAMA ET AL: "Withanoside IV improves hindlimb function by facilitating axonal growth and increase in peripheral nervous system myelin level after spinal cord injury", NEUROSCIENCE RESEARCH, ELSEVIER, SHANNON, IR, vol. 58, no. 2, 1 June 2007 (2007-06-01), pages 176 - 182, XP022100926, ISSN: 0168-0102, DOI: 10.1016/J.NEURES.2007.02.014 *

Also Published As

Publication number Publication date
EP3359177A1 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
Johnson et al. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma
Spampanato et al. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Bianchi et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome
Viviani et al. Glia increase degeneration of hippocampal neurons through release of tumor necrosis factor-α
Deckwerth et al. Neurites can remain viable after destruction of the neuronal soma by programmed cell death (apoptosis)
Fischer et al. Cholinergic amacrine cells are not required for the progression and atropine-mediated suppression of form-deprivation myopia
Kaplan et al. Guillain‐Barre syndrome in the United States, 1978–1981: additional observations from the national surveillance system
AU676491B2 (en) Immunopotentiatory agents
Miller Epidemiology, etiology, and natural treatment of seasonal affective disorder.
Villeneuve et al. Estrogens in tardive dyskinesia in male psychiatric patients
Xiao et al. Neuroprotection and enhanced neurogenesis by tetramethylpyrazine in adult rat brain after focal ischemia
RU2183959C2 (ru) Применение производных к-252а для лечения расстройств периферической или центральной нервной системы и избыточной выработки цитокина
EP0610433A1 (en) Compositions containing k-252 compounds for potentiation of neurotrophin activity
Porter et al. Aphthous stomatitis—an overview of aetiopathogenesis and management
Dau et al. Transformation of lymphocytes from patients with multiple sclerosis: use of an encephalitogen of human origin, with a report of a trial of immunosuppressive therapy in multiple sclerosis
Schuster et al. Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3, 4-dihydroxyphenylalanine-induced dyskinesia
DE69837324T2 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
US20010033872A1 (en) Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and St. John's Wort for the treatment of mental disturbances
Lagreze et al. The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro
Valerio et al. β-Sitosterol down-regulates some pro-inflammatory signal transduction pathways by increasing the activity of tyrosine phosphatase SHP-1 in J774A. 1 murine macrophages
US20100260755A1 (en) Ibudilast and immunomodulators combination
Stitz et al. Pathogenesis of Borna disease
Kusaka et al. An adult-onset case of sporadic motor neuron disease with basophilic inclusions
Agarwal et al. Oculohypotensive effects of Foeniculum vulgare in experimental models of glaucoma
Zhang et al. Prepulse inhibition in rats with temporary inhibition/inactivation of ventral or dorsal hippocampus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15798547

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2015798547

Country of ref document: EP